Secukinumab 300mg/2ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Drugs used in rheumatic diseases and gout
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Secukinumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Secukinumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Secukinumab on the MHRA register
Cosentyx 300mg/2ml solution for injection pre-filled pens
WHO defined daily dose (DDD)
10 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Secukinumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(14)
Secukinumab for treating active ankylosing spondylitis (TA407)
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
Upadacitinib for treating active ankylosing spondylitis (TA829)
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Tofacitinib for treating active ankylosing spondylitis (TA920)
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA918)
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Spondyloarthritis in over 16s: diagnosis and management (NG65)
Bimekizumab for treating active psoriatic arthritis (TA916)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
22 to 31 days
Mechanism
Interleukin-17 (IL-17) is a family of proinflammatory cytokines that mediate normal inflammatory and immune responses.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
150 mg
Half-life
22 to 31 days
[L39600]…
Volume of distribution
7.10 to 8.60 L
Metabolism
[L39600]
Clearance
0.14 L
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L39600]
In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
[L42280]
It is also indicated for the treatment of active psoriatic arthritis (PsA). In the US, it is approved for patients two years of age and older [L39600] while in Europe, it is used alone or in combination with [methotrexate] in patients six years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
[L42280]
Secukinumab is also indicated in the treatment of active enthesitis-related arthritis (ERA). In the US, it is approved for patients four year of age and older.
[L39600]
In Europe, it is used alone or in combination with [methotrexate] in patients six years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
[L42280]
In the US, secukinumab is indicated for the treatment of adults with active ankylosing spondylitis, non-radiographic axial spondyloarthritis with objective signs of inflammation, moderate to severe hidradenitis suppurativa.
[L48771]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1351 interactions
[L39600]
IL-17A is a member of IL-17 with the most prominent role in host defence and autoimmunity.[A249835] IL-17A is often upregulated in several autoimmune disorders, such as psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis, making it an important therapeutic target.[A249805][L42280] IL-17A is also more potent than IL-17F, another member of IL-17, with a much greater affinity to the IL-17 receptor.[A249835] Secukinumab selectively binds to and inhibits IL-17A,[A249805] preventing its interaction with the IL-17 receptor and activation of the IL-17 receptor signalling pathway associated with inflammatory processes.[A249835][L42280]
As the formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation, secukinumab can potentially alter the concentrations of CYP substrate drugs with a narrow therapeutic index.[L39600]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L39600]
Following subcutaneous injection, the Cmax is reached in five to six days.
[A249805]
Steady-state concentrations were achieved by week 24 following the every 4-week dosing regimens.
In healthy subjects and subjects with plaque psoriasis, bioavailability ranged from 55% to 77% following subcutaneous administration.
[L39600]
[L39600]
The mean elimination half-life was 27 days.
[L42280]
[L39600]
These values suggest that secukinumab undergoes limited distribution to peripheral compartments.
[L42280]
The volume of distribution increases with body weight. Following subcutaneous administration of a single 300 mg dose, drug concentrations in interstitial fluid in lesional and non-lesional skin of plaque psoriasis subjects ranged from 27% to 40% of those in serum at one and two weeks.
[L39600]
[L39600]
[L39600]
Clearance of secukinumab is dose- and time-independent,[A249805][L42280] and is expected to increase with body weight.
[L39600]
Proteins and enzymes this drug interacts with in the body
PMID:24120361
Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation .
PMID:17911633 PMID:18684971 PMID:19825828 PMID:21350122 PMID:24120361 PMID:8676080
Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity).
In airway epithelium, mediates neutrophil chemotaxis via induction of CXCL1 and CXCL5 chemokines (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Effector cytokine of a subset of gamma-delta T cells that functions as part of an inflammatory circuit downstream IL1B, TLR2 and IL23A-IL12B to promote neutrophil recruitment for efficient bacterial clearance (By similarity).
Effector cytokine of innate immune cells including invariant natural killer cell (iNKT) and group 3 innate lymphoid cells that mediate initial neutrophilic inflammation (By similarity). Involved in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection .
PMID:21350122
Upon acute injury, has a direct role in epithelial barrier formation by regulating OCLN localization and tight junction biogenesis (By similarity). As part of the mucosal immune response induced by commensal bacteria, enhances host's ability to resist pathogenic bacterial and fungal infections by promoting neutrophil recruitment and antimicrobial peptides release (By similarity).
In synergy with IL17F, mediates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms (By similarity). Enhances immunity against West Nile virus by promoting T cell cytotoxicity (By similarity).
May play a beneficial role in influenza A virus (H5N1) infection by enhancing B cell recruitment and immune response in the lung (By similarity). Contributes to influenza A virus (H1N1) clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity)
ATC L04AC10
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Secukinumab
Patent information
All patents expired, 1 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: